Life Sciences Reports

Executive Intelligence

Life Sciences Reports

Regulatory, funding, leadership, market and commercial updates selected for life-science executives.

RegulatoryMHRA · 3 weeks ago

Guidance: The Centres of Excellence for Regulatory Science and Innovation programme (CERSIs)

A national programme to help drive advancements in healthcare, to ensure patients benefit from innovation and new treatments sooner.
Read full report
RegulatoryMHRA · 3 weeks ago

Field Safety Notices: 21 to 25 September 2026

List of Field Safety Notices from 21 to 25 September 2026.
Read full report
RegulatoryMHRA · 3 weeks ago

Field Safety Notices: 21 to 25 September 2026

List of Field Safety Notices from 21 to 25 September 2026.
Read full report
RegulatoryMHRA · 3 weeks ago

MHRA Safety Roundup: September 2026

Summary of the latest safety advice for medicines and medical device users
Read full report
RegulatoryMHRA · 3 weeks ago

MHRA Safety Roundup: September 2026

Summary of the latest safety advice for medicines and medical device users
Read full report
RegulatoryMHRA · 3 weeks ago

MHRA Safety Roundup: September 2026

Summary of the latest safety advice for medicines and medical device users
Read full report
RegulatoryFDA · 4 weeks ago

FDA Approves First Treatment for MCT8 Deficiency

The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in…
Read full report
RegulatoryFDA · 4 weeks ago

FDA intends to evaluate changes to the PMTA regulatory framework

FDA is carefully reviewing its experience implementing the Premarket Tobacco Product Application (PMTA) rule, as well as recent judicial developments, including a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework.
Read full report
RegulatoryMHRA · 4 weeks ago

Professor Dame Anna Dominiczak, Professor Alison Strath, and Fiona Cohrane: Catalysing the medicines ecosystem in Scotland

Scotland’s growing commercial research infrastructure and strong NHS, academic and industry partnerships are helping widen access to clinical trials, accelerate adoption and strengthen the UK life sciences ecosystem.
Read full report
RegulatoryMHRA · 4 weeks ago

Five new commissioners appointed to the Commission on Human Medicines (CHM)

The CHM provides independent expert advice to ministers on the safety, quality and efficacy of medicines.
Read full report
RegulatoryMHRA · 4 weeks ago

MHRA welcomes sentencing after fraud convictions over falsely certified medical devices

Following convictions related to falsely certified medical devices, the MHRA has welcomed the sentencing in a long-running enforcement investigation.
Read full report
RegulatoryFDA · 4 weeks ago

Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions

A U.S. Food and Drug Administration investigation resulted in a federal court order, dated Sept. 21, 2026, stopping a warehouse operator from distributing FDA-regulated products including food, drugs, medical devices, and cosmetics until it fixes its operations to meet federal legal requirements.
Read full report
RegulatoryMHRA · 4 weeks ago

MHRA approves lurbinectedin for adults with extensive-stage small cell lung cancer   

As with all licensed medicines, the MHRA will keep the safety and effectiveness of lurbinectedin under close review.
Read full report
RegulatoryMHRA · 4 weeks ago

Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39

B. Braun Melsungen AG has notified the MHRA that errors have been identified in the Patient Information Leaflet (PIL) included in some batches of Meropenem 1000 mg powder and solvent for solution for infusion.
Read full report
RegulatoryMHRA · 1 month ago

Field Safety Notices: 14 to 18 September 2026

List of Field Safety Notices from 14 to 18 September 2026.
Read full report
RegulatoryMHRA · 1 month ago

Clinical trials for medicines: Good clinical practice inspections

Information relating to good clinical practice (GCP) inspections.
Read full report
RegulatoryMHRA · 1 month ago

Beyond ADMET: AI for medicines safety – survey

The MHRA and the Regulatory Innovation Office (RIO) invite organisations to share their views on the use of artificial intelligence (AI) in medicines development.
Read full report
RegulatoryMHRA · 1 month ago

Funding opportunity launched to strengthen UK regulatory science and support healthcare innovation  

Four new centres of excellence will bring together expertise across academia, industry, healthcare and regulation to keep pace with advances in healthcare and life sciences
Read full report
RegulatoryFDA · 1 month ago

FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing

The FDA today issued a direct final rule that updates its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use before they’re tried in humans.
Read full report
RegulatoryEMA · 1 month ago

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026

12 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its September 2026 meeting.The committee recommended…, CHMP statistics Key figures from the September 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency, CHMP statistics:…,…
Read full report
RegulatoryFDA · 1 month ago

FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.
Read full report
RegulatoryMHRA · 1 month ago

Radiofrequency (RF) Safety Considerations for Wireless Cardiotocography (CTG) Monitoring Systems (DSI/2026/012)

The MHRA has conducted a review into the use of wireless cardiotocography (CTG) systems that use radiofrequency (RF) telemetry channels. Signal crossover, erroneous CTG traces and signal dropouts have been identified as patient safety risks associated with these devices.
Read full report
RegulatoryMHRA · 1 month ago

Class 4 Medicines Defect Notification: Martindale Pharmaceuticals Ltd, Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150ml, EL(26)A/38

Martindale Pharmaceuticals has informed the MHRA of an error with the linear barcode of some batches of Clobazam 5mg/5mL and 10mg/5mL Oral Suspension 150mL.
Read full report
RegulatoryMHRA · 1 month ago

Pre-submission Advice & Support for Innovative Medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) offer a pre-submission service before applying for medicines Marketing Authorisations and clinical variations innovative medicines.
Read full report